Table 3.

Frequency of fluoropyrimidine-related toxicity in the two groups split into wild type and specific DPYD variants

	Intervention group (DPYD guided)a						Control groupa
	CH (D949V, HapB3), n = 1	HT (D949V), n = 5	HT (DPYD13), n = 3	HT (DPYD2A), n = 1	HT (HapB3), n = 12	Wild type, n = 208	CH (DPYD2A-HapB3), n = 1	HT (D949V), n = 4	HT (DPYD13), n = 1	HT (DPYD2A), n = 7	HT (HapB3), n = 27	HO (HapB3), n = 2	Wild type, n = 450
Relative dose intensity first cycleb	50 (50-50)	50 (50-50)	50 (50-50)	50 (50-50)	49 (38-50)	96 (75-100)	100 (100-100)	94 (75-100)	80 (80-80)	100 (100-100)	98 (75-100)	100 (100-100)	98 (50-100)
Overall grade ≥3 toxicity	0	1 (20)	1 (33)	1 (100)	2 (17)	58 (28)	1 (100)	0	0	5 (71)	6 (22)	0	100 (22)
Stop of FP treatment due to toxicity	0	0	0	0	0	14 (6.7)	1 (100)	0	0	1 (14)	1 (3.7)	0	27 (6.0)
FP-related hospitalization	0	0	0	0	0	23 (11)	1 (100)	0	0	5 (71)	2 (7.4)	0	32 (7.1)
Worst FP grade registered.
Grade 3 toxicity	0	1 (20)	1 (33)	1 (100)	2 (17)	51 (25)	0	0	0	2 (29)	5 (19)	0	87 (19)
Grade 4 toxicity	0	0	0	0	0	6 (2.9)	1 (100)	0	0	1 (14)	1 (3.7)	0	9 (2.0)
Grade 5 toxicity (death)	0	0	0	0	0	1 (0.5)	0	0	0	2 (29)	0	0	4 (0.9)
Grade ≥3 gastrointestinal toxicity	0	0	0	1 (100)	2 (17)	31 (15)	0	0	0	4 (57)	5 (19)	0	51 (11)
Grade ≥3 hematological toxicity	0	0	0	0	0	11 (5.3)	1 (100)	0	0	2 (29)	1 (3.7)	0	22 (4.9)
Grade ≥3 cardiac toxicity	0	1 (20)	0	0	0	7 (3.4)	0	0	0	0	0	0	10 (2.2)
Grade 3 PPE	0	0	1 (33)	0	0	8 (3.8)	0	0	0	0	1 (3.7)	0	13 (2.9)
Grade ≥3 other toxicity	0	0	0	0	0	2 (1.0)	0	0	0	0	0	0	2 (0.4)

FP, (5-fluorouracil, capecitabine, tegafur(S-1));

PPE, palmar plantar erythrodysesthesia; CH, compound heterozygous; HT, heterozygous; HO, homozygous.

^an (%).

^bMean in % of normal dose of FP drug relative to regimen. (min-max); all toxicity reported in this table is related to FP.